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Familial amyloid precursor protein mutants cause
caspase-6-dependentbutamyloidb-peptide-independent
neuronal degeneration in primary human
neuron cultures.
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Although familial Alzheimer disease (AD)-associatedautosomaldominantmutantshavebeenextensivelystudied, little isknown
about the underlying molecular mechanisms of neurodegeneration induced by these mutants in AD. Wild-type, Swedish
or London amyloid precursor protein (APP) transfection in primary human neurons induced neuritic beading, in which several
co-expressed proteins, such as enhanced green ﬂuorescent protein, red ﬂuorescent protein (RFP)-tau and RFP-ubiquitin,
accumulated.APP-inducedneuriticbeadingwasdependentoncaspase-6(Casp6),becauseitwasinhibitedwith5lMz-VEID-fmk
or with dominant-negative Casp6. Neuritic beading was independent from APP-mediated amyloid b-peptide (Ab) production,
because the APPM596V (APP
MV) mutant, which cannot generate Ab, still induced Casp6-dependent neuritic beading. However,
the beaded neurons underwent Casp6- and Ab-dependent cell death. These results indicate that overexpression of wild-type or
mutant APP causes Casp6-dependent but Ab-independent neuritic degeneration in human neurons. Because Casp6 is activated
early in AD and is involved in axonal degeneration, these results suggest that the inhibition of Casp6 may represent an efﬁcient
early intervention against familial forms of AD. Furthermore, these results indicate that removing Ab without inhibiting Casp6
may have little effect in preventing the progressive dementia associated with sporadic or familial AD.
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Strong activity of caspase-6 (Casp6) determined by immuno-
histochemistry or immunoprecipitation, with neoepitope
antisera to the active p20 subunit of Casp6 and to tau
(microtubule-associated protein tau) or a-tubulin (Tub)
cleaved by Casp6 (tauDCasp6, tau cleaved by Casp6; or
TubDCasp6, tubulin cleaved by Casp6), is present in the
hippocampus and affected cortices of sporadic and familial
forms of Alzheimer disease (AD).
1–4 Casp6 activity is present
in the neuropil threads, neuroﬁbrillary tangles and neuritic
senile plaques of the brain of mild cognitively impaired and
mild-to-severe AD individuals.
2 Casp6 is also activated in the
entorhinal cortex of non-cognitively impaired aged individuals
thatneverthelesshadthelowestglobal cognitivescoresofthe
group.
2 As the entorhinal cortex is the area ﬁrst affected in
AD brains, these ﬁndings suggest that Casp6 could be an
early instigator of AD. In contrast to the other two short
pro-domain effector caspases (Casps), caspase-3 (Casp3) and
caspase-7 (Casp7), Casp6 has not been well investigated.
The high levels of active Casp6 in familial AD brain
1 incite
the question of whether familial AD-associated mutant
proteins induce Casp6 activation and if this activation
depends on Ab. Familial AD occurs either via APP duplication
or single point mutations of the amyloid precursor protein
(APP) and Presenilin genes.
5,6 No studies have reported the
effect of familial AD-associated mutant proteins on Casp6
activity. However, expression of the APP V717I London (Lo)
mutant induces Ab-mediated Casp-dependent condensed
chromatin in primary cortical neurons,
7 and expression of the
APP Lomutation induces DNAfragmentation in COSor COS-
like cell lines.
8,9 Condensed chromatin and DNA fragmenta-
tion are both indicative of apoptotic cell death but the exact
Casp responsible was not clearly identiﬁed in these studies.
Expression of the APP Swedish (Sw) mutation increases the
vulnerability of transfected PC12 cells to oxidative stress and
the cells undergo Casp3-dependent cell death.
10 Because
familial mutants increase amyloid b-peptide (Ab) production,
Ab is generally thought to cause AD by synaptic or neuronal
toxicity (reviewed in Selkoe and Podlisny
11). However, it is
also possible that yet undiscovered natural functions are
disrupted in mutant genes associated with familial AD, and
cause undue stress to neurons before or independently from
Ab production. Indeed, cellular stresses induce overproduc-
tion of Ab in a Casp-dependent manner,
12,13 thus placing Ab
downstream of an initial stress.
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www.nature.com/cddisPro-Casp-6 (Casp6) is a cytosolic cysteinyl protease
zymogen that is activated by self- or exo-proteolytic
processing into a p20 and p10 subunit that reassemble to
formthehetero-tetramericactiveCasp6.
14,15 Casp6hasoften
beenplaceddownstreamofCasp3andCasp7intheapoptotic
cascade, as it is proteolytically processed and activated by
these two enzymes.
16 However, Casp6 is active in the
absence of Casp3 and Casp7 in serum-deprived human
primary neuronal cultures, and Casp6 activity precedes
effector or initiator Casp activation in several cell types.
13,17–19
Unlike the other effector Casps, active Casp6 is not always
associated with apoptotic cell death. In AD, active Casp6-
positive neurons do not show apoptotic morphology.
3 Micro-
injection of active Casp6, but not Casp3 or Casp7, induces a
protracted type of cell death in human neurons.
20 Similarly,
activation of Casp6 in HEK293T cells does not induce cell
death detectable by MTT reduction, sub-G1 content assessed
by FACS analyses or Casp3 activation.
15
Recently, Casp6 has been recognized as highly important
in inducing axonal degeneration, whereas Casp3 induces cell
death in APP-mediated death receptor 6 signaling in trophic-
factor-deprived commissural, sensory and motor mouse
neurons.
21 Although active Casp6 cleaves several neuronal
proteins associated with AD, such as APP, tau,
22 and
presenilin 1 and 2,
23 Casp6 also cleaves crucial cytoskeleton
proteins including a-Tub, and a-actin-regulating post-synaptic
density proteins, drebrin, spinophillin, a-actinin-1 and -4.
4
Therefore, the activation of Casp6 may alter the neuronal
cytoskeleton and be responsible for the abundant levels of
dystrophic neurites present in AD brains.
Dystrophicneuritescontainingseverelyalteredcytoskeletal
organizations are a primary feature of AD pathology. Often
characterized by abnormal tau and phosphorylated tau
immunoreactivity, dystrophic neurites in AD show axonal
swellings, varicosities, densely packed organelles, membra-
nous dense bodies and vesicular proﬁles.
24,25 Many of these
features are present in the brain of aged APP Sw mutant
transgenic mice.
26 Overexpression of wild-type and mutant
APP associated with familial AD induce axonal transport
defects that result in organelle accumulation.
26–31 Neuronal
degeneration in APP wild-type transgenic mice brains is also
associated with memory impairment.
32 Surprisingly, in some
animalmodels, APP-mediated axonopathiesare independent
of Ab.
26,33
As Casp6 is predominantly activated in sporadic and familial
AD brains, in this study, we investigated if APP wild-type or
familial AD-associated APP mutants induced Casp6 activity.
Results
Wild-type APP695 (APP
WT), Sw mutant APP695 (APP
Sw)o r
the Lo mutant APP695 (APP
Lo) induce Casp6-dependent
neuritic enhanced green ﬂuorescent protein (EGFP)-
positive beading in transfected primary human
neurons. To assess whether familial AD-associated
mutants activate Casp6 in terminally differentiated human
neurons, primary cultures were transfected with pBudEGFP/
APP
WT,/ A P P
Sw or /APP
Lo cDNA constructs. The APP and
EGFP are independently expressed from the human
elongation factor 1-a and the cytomegalovirus (CMV)
promoters, respectively. EGFP, thus, serves as a marker of
transfection efﬁciency. The APP
WT represents overexpression
of APP associated with trisomy 21 and a few FAD families.
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The expression of APP from these constructs was conﬁrmed
in Neuro-2a (N2a) cells, which in contrast to human neurons
can be transfected with high efﬁciency for biochemical
analyses (Supplementary Figure 1). Only 2mgo ft o t a l
proteins from the transfected cells were loaded on the
western blot to avoid endogenous APP detection. Under
these conditions, robust expression of APP was detected from
each of the APP-expressing constructs, whereas none was
observed in EGFP alone or mock-transfected cells; thus
conﬁrming APP expression under the CMV promoter of the
pBud bigenic vector. As the CMV promoter is active in human
primary neurons, these constructs were delivered with a
biolistic particle delivery system, the most efﬁcient transfection
approach, as human neurons are not amenable to general
viral infection systems or overly sensitive to liposome-
mediated transfections. In the absence of APP
co-expression, the EGFP was homogeneously distributed in
the cell body and neurites of transfected human primary
neurons (Figure 1a and 1a inset). When APP
WT,A P P
Sw or
APP
Lo were co-expressed with EGFP, EGFP was often
detected in an enlarged cell soma and appeared as beads-on-
a-string within the neurites (Figure 1b–d). This effect of APP
on the EGFP distribution conﬁrms the expected expression of
APP from the pBudEGFP/APP constructs. Morphologically,
EGFP-positive beads occurred at stochastic intervals and in
varying sizes (1–2.5mm) along the neurites (Figure 1c inset).
Nuclear staining with Hoechst 33342 demonstrated that the
larger EGFP-positive agglomerates overlapped with nuclei,
whereas the smaller beads did not (Figure 1b–d). Under
phase contrast, neuritic EGFP-positive beads overlapped with
a slight enlargement and darkened area of the neurite
resembling varicosities, in the absence of compromised
membrane integrity (Figure 1e).
Quantitative analyses demonstrated that 40–60% APP
WT-,
APP
Sw- or APP
Lo-transfected neurons developed an EGFP-
positive beaded morphology by 48 to 72h post transfection
(Figure 1f). In contrast, EGFP expression in the absence of
APP co-expression showed o10% neuronal beading
between 24 to 72h of transfection. Together, these results
indicate that APP
WT, APP
Sw or APP
Lo expression cause an
agglomeration of EGFP within neurites of human neurons.
To investigate whether Casp6 activation was involved in
neuritic EGFP-positive beading, APP
WT-, APP
Sw- or APP
Lo-
transfected neurons were treated with 5mM of the Casp6
peptide inhibitor, z-VEID-fmk. Treatment with the Casp6
inhibitor signiﬁcantly decreased EGFP-positive beading
morphology in APP
WT-, APP
Sw- or APP
Lo-transfected
neurons for up to 72h (Figure 1f). Casp6 has recently been
shown to be associated with neurodegeneration by causing
beading of Tub in mouse neurons.
21 We conﬁrmed Casp6-
dependent Tub beading in human neurons (Supplementary
Figure 2). Therefore, these results indicate that APP
WT,
APP
Sw or APP
Lo overexpression cause Casp6-dependent
neuritic degeneration.
Because peptide inhibitors of Casps can be promiscuous,
we conﬁrmed the involvement of Casp6 activity in APP-
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Cell Death and Diseasemediated neuritic beading with the catalytically mutated form
of proCasp6, proCasp6C163A. The dominant-negative
(DN) nature of proCasp6C163A was ﬁrst tested on the
self-activated form of Casp6 lacking its pro-domain
(p20p10Casp6) in the human colon carcinoma HCT116 cell
line. In these, the ﬂuorogenic assay revealed that expression
of proCasp6C163A completely abrogated p20p10Casp6-
mediated VEIDase activity (Figure 2a). Western blot analyses
of the transfected cells showed that proCasp6C163A was
expressed as a 32kDa protein, whereas p20p10Casp6
migrated at 28kDa, as expected (Figure 2b). Expression of
p20p10Casp6 generated the p20 and p10 subunits of the
active Casp6, consistent with the activity detected in
Figure 2a. Co-expression of the proCasp6C163A with
Figure1 APP
WT,APP
SworAPP
LoinduceCasp6-dependentEGFP-positiveneuriticbeadinginprimaryhumanneurons.(a–d)FluorescencemicrographsshowingEGFP,
Hoechst DNA stain and a merge of EGFP and Hoechst in (a) pBudEGFP- (b) pBudEGFP/APP
WT-, (c) pBudEGFP/APP
Sw- and (d) pBudEGFP/APP
Lo-transfected human
neurons at 48h post transfection. Insets given in panel a and b represent a higher magniﬁcation of the EGFP-positive neurites. Each picture was taken and enlarged at the
same magniﬁcation. Arrows indicate the cell body of the transfected neuron. (e) Overlay of phase contrast, EGFP ﬂuorescence and Hoescht-stained neuron depicted in
Figure1c.Thelowerpanelsrepresentaside-by-sidecomparisonoftheEGFP-positivebeadswiththephasecontrastimage.(f)PercentageofEGFP-positivebeadedneurons
relative to all EGFP-positive neurons incubated without ( VEID) or with 5mM z-VEID-fmk (þVEID) for 24, 48 or 72h. Data represents mean of three independent
experiments±S.E.M. Each experiment represents 50–150 EGFP-positive neurons. *Represents a statistically signiﬁcant difference (Po0.01) between EGFP and APP
versus EGFP only transfected neurons (paired for –VEID or þVEID). **Represents a statistically signiﬁcant difference of Po0.001 between –VEID and þVEID treatments
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Cell Death and Diseasep20p10Casp6 reduced the level of the proCasp6C163A
protein and increased the level of the p20 subunit indicating
that proCasp6C163A was slightly processed by the active
Casp6, and did not inhibit processing of the p20p10Casp6.
These results are consistent with the hypothesis that DN
inhibitors inhibit enzymatic Casp activity by generating a
hetero-tetramericenzymecontainingcatalyticallyinactivep20
subunits of the cognate Casp, and established the DN nature
of proCasp6C163A (DN Casp6). Co-delivery of DN Casp6
with the pBudEGFP/APP
Lo in human neurons signiﬁcantly
prevented EGFP-positive neuritic beading, thus conﬁrming
the involvement of Casp6 activity in APP-mediated neuritic
beading (Figure 2c).
APP
WT-, APP
Sw- or APP
Lo-induced EGFP-positive beads
also contain tau and ubiquitin (Ub) proteins. To assess
whether beading was speciﬁc to EGFP, red ﬂuorescent
protein (RFP)-tau was transfected alone or co-transfected
with pBudEGFP, or with pBudEGFP/APP
WT, /APP
Sw
or /APP
Lo. RFP-tau was expressed and localized in the cell
soma and neurites of neurons (Figure 3a). In RFP-tau and
EGFP co-transfected neurons, both proteins showed an
overlapping homogenous distribution in the neurons. In RFP-
tau neurons co-transfected with pBudEGFP/APP
WT, /APP
SW
or /APP
Lo, EGFP- and RFP-positive beads appeared.
As the accumulation of Ub inclusions is a common feature
of degenerating neurites, RFP-Ub was also co-transfected
with EGFP and APP
Lo in neurons. By itself, RFP-Ub evenly
distributed in the cell soma and in neurites (Figure 3b).
However, co-transfection of RFP-Ub with EGFP and APP
Lo
also caused RFP-Ub to accumulate in EGFP-positive beads.
Together, the results indicate that the induced neuritic
beading was not exclusive to EGFP, as it occurred with
RFP-tau and RFP-Ub.
Neuritic beading is independent of Ab production in
APP-transfected neurons. To determine whether neuritic
beading may be a consequence of Ab overproduction in
APP-transfected neurons, we transfected human neurons
with the APP
MV construct, in which the methionine 596 was
mutated to a valine to prevent processing by b-secretase and
generation of Ab, as previously demonstrated.
34 The APP
MV
protein was expressed from the pBudEGFP/APP
MV
construct at levels similar to those of the APP
SW protein
(Supplementary Figure 1). In human neurons, pBudEGFP/
APP
MV induced EGFP-positive beads at a level consistently
observed in pBudEGFP/APP
WT-transfected neurons
(Figure 4a). Similarly, the presence of the Lo mutation in
APP
MV also generated 30.05±6.15% beading (n¼444
transfected cells), indicating that the APP
MV-mediated
beading was not synergistic with the APP
Lo-mediated
beading. z-VEID-fmk signiﬁcantly inhibited APP
MV-induced
EGFP-positive beading, indicating that EGFP-positive
beading was dependent on Casp6 activity (Figure 4b). We
have previously reported that low levels of Ab1 42 or Ab1 40
induce neuritic beading of human neurons after 72h of
treatment and also render neurons vulnerable to a secondary
insult.
35 To assess if Ab1 42 may function synergistically with
Ab-independent neuritic beading in pBudEGFP/APP
MV-
transfected neurons, these were treated with 50nM Ab1 42
or control reverse peptide Ab42 1.A b1 42 increased levels of
beading in pBudEGFP/APP
MV-transfected neurons after 24h
of incubation, but the increase did not reach statistical
signiﬁcance compared with Ab42 1 (Figure 4c). However,
beading in APP
MV-transfected cells treated with Ab1 42 was
signiﬁcantly inhibited by DN Casp6. These results conﬁrmed
Figure 2 DN form of Casp6 inhibits APP
Lo-mediated EGFP-positive beading
inprimaryhumanneurons.(a)SpeciﬁcVEIDase activity and(b)westernblot analysis
with anti-p10Casp6 (top panel), 10630 neoepitope antiserum against p20 (middle
panel)andanti-b-actin(bottompanel)intransfectedHCT116cellularproteinextracts.
(c) Percentage of EGFP-positive beaded neurons in cultures transfected with
pBudEGFP or pBudEGFP/APP
Lo with pCep4b vector control ( DN Casp6) or
pCep4b-DN Casp6(þ DN Casp6)at24and48hposttransfection. Data represents
mean±S.E.M. of three independent experiments. **Represents a statistically
signiﬁcant difference between –DN Casp6 andþDN Casp6 (Po0.05)
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Cell Death and Diseasethat the beading was dependent on Casp6 activity, but was
independent of Ab.
APP
WT, APP
Sw or APP
Lo cause Casp6-dependent EGFP-
positive cell death. To determine whether APP expression
induces cell death, primary human neurons were transfected
with pBudEGFP/APP
WT, /APP
Sw or /APP
Lo, and the total
number of EGFP-expressing neurons monitored live by
ﬂuorescence microscopy every 24h for up to 72h. Results
were expressed relative to the 24h time point (Figure 5A).
EGFP-expressing neurons were maintained up to 72h;
however, EGFP-positive beading in pBudEGFP/APP
WT-,
pBudEGFP/APP
Sw- and pBudEGFP/APP
Lo-transfected
neurons decreased by 50, 44 and 36%, respectively, within
48h post-transfection. After 72h, only 20% of EGFP-positive
neurons remained in pBudEGFP/APP-transfected neurons.
Treatment with 5mM of z-VEID-fmk signiﬁcantly prevented
EGFP-positive neuronal dropout in neurons transfected
with pBudEGFP/APP
WT or pBudEGFP/APP
Lo at the 48h
time point (Figure 5A). By 72h, z-VEID-fmk signiﬁcantly
attenuated neuronal dropout levels in all pBudEGFP/APP-
transfected neurons. Furthermore, co-expression of the DN
Casp6 with the pBudEGFP/APP
Lo inhibited EGFP-positive
neuronal dropout (Figure 5B). To conﬁrm that the loss of
EGFP-positive neurons was due to cell death, we assessed
condensed chromatin with the cell permeable dye Hoechst
33342 at 48h post transfection. In all, 50, 51 and 39% of
pBudEGFP/APP
WT-, /APP
Sw- or APP
Lo-transfected neurons,
respectively, exhibited condensed chromatin that was
completely inhibited by z-VEID-fmk (Figure 5C). Likewise,
the condensed chromatin in pBudEGFP/APP
Lo-transfected
neurons was abolished by co-expression of DN Casp6
(Figure 5D). Additionally, transfected neurons counter-
stained with terminal deoxynucleotidyl transferase-mediated
biotinylated UTP nick end labeling (TUNEL)-Red and
Hoechst 33342 showed that beaded APP
Lo-transfected
neurons had both condensed chromatin and fragmented
DNA (Figure 5E). Collectively, these results indicate that
expression of APP
WT, APP
Sw or APP
Lo cause Casp6-
dependent neuronal cell death.
Cell death is dependent on Ab in APP-transfected
neurons. To determine whether cell death may be due to
Ab, we measured condensed chromatin in pBudEGFP/
APP
MV-transfected human neurons. In contrast to the
pBudEGFP/APP
WT-transfected neurons, pBudEGFP/
APP
MV-transfected human neurons did not show an
increase in condensed chromatin after 48h of transfection
(Figure 6a). Similarly, the pBudEGFP/APP
MV/Lo-transfected
cells showed only 12.2±2.5% condensed chromatin
(n¼444 transfected neurons). However, when treated with
Ab1 42, but not reverse peptide Ab42 1, a signiﬁcant increase
in condensed chromatin was observed in the APP
MV-
transfected neurons (Figure 6b). Condensed chromatin was
present in 30–70% of the beaded neurons but rare in non-
beaded neurons (Figure 6c). Furthermore, the DN Casp6
decreased Ab1 42-mediated condensed chromatin in beaded
neurons indicating that Ab-mediated cell death in human
neurons expressing APP
MV is also dependent on Casp6
activity (Figure 6c). Together, these results indicate that the
Ab generated from APP overexpression in transfected
neurons is responsible for cell death.
Discussion
In this study, we showed that conditions associated with
familial AD, such as APP
WT overexpression or the expression
of APP mutants, induce Casp6-dependent but Ab-indepen-
dent neuritic degeneration in primary cultures of human
Figure 3 APP-induced neuritic beads contain tau and Ub proteins in addition to
EGFP. Fluorescence micrographs of EGFP, RFP or a merged image of EGFP and
RFPinhumanneuronstransfectedwith(a)RFP-tauonly,RFP-tauandpBudEGFP,
or RFP-tau and pBudEGFP/APP
WT, pBudEGFP/APP
Sw, or pBudEGFP/APP
Lo or
(b) RFP-Ub or RFP-Ub and pBudEGFP/APP
Lo. *n indicates a transfected neuron,
*a indicates a transfected astrocyte
APP mutants induce Casp6-dependent neurodegeneration
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Cell Death and Diseaseneurons. Overexpression of APP
WT, APP
Sw or APP
Lo in
human neurons resulted in the formation of neuritic swellings
or varicosities, wherein proteins such as EGFP, RFP-tau and
RFP-Ub accumulated rather than homogeneously distributed
within the neurites. Inhibition of APP-mediated neuritic
beading by the irreversible z-VEID-fmk peptide inhibitor and
DN Casp6, conﬁrmed the importance of Casp6 for neuritic
beading. As overexpression of APP
WT or APP mutants result
in increased levels of Ab,
11,36 it was logical to associate Ab
with Casp6-dependent neuritic beading. However, in this
study, we showed that Ab was not responsible. The APP
MV
mutated at the b-secretase site and thus unable to generate
Ab,
34 retained its ability to induce Casp6-dependent neuritic
beading. Furthermore, the addition of physiologically high
levels of Ab1 42 to the APP
MV-transfected neurons did not
enhance the level of neuritic beading. That neuritic disruption
is distinct from Ab production is consistent with recently
published results that showed that axonal defects are not
dependent on Ab in an APP overexpression murine model.
33
That Casp6 is responsible for neurodegeneration is entirely
consistent with the recently emerging role for Casp6 in
neuronal degeneration of mouse primary neurons.
21 This
data suggest that Casp6 may also be responsible for the
previously reported axonopathy and transport deﬁcits caused
by APP
WT, APP
Sw or APP
Lo overexpression in vitro and
in vivo.
26,27,29 Together with the present observations, the
ability of Casp6 to cleave several important cytoskeletal
proteinsinhumanneurons
4andthestrongactivityofCasp6in
neuropil threads, neuritic plaques and neuroﬁbrillary tangles
of sporadic and familial AD neurons
1–3 suggest that Casp6
has a predominant role in the neurodegenerative events of
AD. These ﬁndingsindicatethat inhibitionof Casp6may bean
efﬁcient treatment against neurodegeneration in AD.
We also showed that APP
WT overexpression or the
expression of APP mutants induced Casp6- and Ab-
dependent cell death. Indeed, APP
WT, APP
Sw or APP
Lo
expression in primary human neurons caused neuronal
dropout, condensed chromatin, and TUNEL staining. This
cell death depended on Casp6 activity, occurred uniquely in
neurons that presented neuritic beads, and was inhibited by
z-VEID-fmk or the DN Casp6. In contrast to neuritic beading,
cell death was caused by Ab, as it was absent in APP
MV-
transfected human neurons, and treatment with 50nM of
extracellular Ab1 42 re-established cell death in APP
MV-
transfected beaded neurons. This is entirely consistent with
a previous report showing that the APP M596I mutant, which
cannot undergo b-secretase cleavage, increases the resis-
tance of APP FAD mutant-expressing cells to apoptosis.
37
Interestingly, in the absence of APP overexpression, con-
centrations of 100nM extracellular Ab1 42 do not induce cell
deathbut reducethe levels ofBcl-2 while increasing the levels
of Bax in human neurons, and renders these exposed
neurons vulnerable to oxidative stress.
35 These results show
that neither APP overexpression nor extracellular Ab are
sufﬁcient to initiate cell death in human neurons but a
combination of the two lowers the threshold of neuronal
resistance to cell death. This phenomenon is consistent with
numerous studies, in which APP
Sw and APP
Lo induced cell
death in COS-NK1, PC12, NT2N, rat and mouse primary
cortical neurons, although the exact culprit was not identiﬁed
in these cells.
7,9,38,39 Although overexpression of APP and Ab
causes neuritic beading in transgenic mice, it does not
produce overwhelming levels of cell death.
40 The ability of
Ab to induce cell death in APP-overexpressing neurons in
culture but not in transgenic mice may be explained by
differences in intrinsic species-speciﬁc cell death pathways or
neuroprotective effects from supporting cells. In AD, there is
aninsigniﬁcantamountof neuronalloss exceptearlyin layerII
of the entorhinal cortex and later in the temporal cortex of
advanced cases of AD.
41 However, neurodegeneration in the
absence of evident cell death, is prominent early in AD, as is
synaptic loss which correlates best with the level of
dementia.
22 Therefore, the toxicity of Ab on APP-transfected
neurons may reﬂect a non-physiological event that occurs
easilyincellculturesbutnotinADbrains.Itisalsoimportantto
note that Casp6 activity is not associated with acute cell death
Figure 4 EGFP-positive beads in APP-transfected human neurons do not depend on Ab overproduction. (a) Percentage of EGFP-positive beaded neurons in
pBudEGFP-, pBudEGFP/APP
WT- or pBudEGFP/APP
MV-transfected neurons after 24 and 48h. *Represents a statistically signiﬁcant difference between pBudEGFP- and
pBudEGFP/ APP-transfected neurons (Po0.05). (b) Percentage of EGFP-beaded neurons transfected with APP
MV and cultured 48h in the absence (–VEID) or presence
(þVEID) of 5mM z-VEID-fmk. *Po0.02. (c) Percentage of EGFP-positive beaded neurons transfected with pBudEGFP/APP
MV and pCep4b (–DN Casp6) or pCep4b-
proCasp6C163A (þDN Casp6) and cultured 24h before treating for an additional 24h with 50nM Ab1 42 or control reverse peptide Ab42 1. *Represents a Po0.02
difference between Ab1 42–DN Casp6 and Ab1 42 þ DN Casp6. No other statistically signiﬁcant differences were obtained. For (a–c), data represents mean±S.E.M. of
three independent experiments
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Cell Death and Diseaseas observed with the other two effector Casps, Casp3 and
Casp7.
15,20 Similarly in AD, the active Casp6 is present in
neurons that do not show apoptotic morphology.
3 Further-
more, Casp6 activity causes neuritic degeneration but not cell
death in primary mouse neurons.
21 Therefore, the intense
Casp6 activity observed in neuropil threads, neuroﬁbrillary
tangles and neuritic plaques is more likely associated with
neurodegeneration than with cell death in AD. From these
results, we conclude that removing Ab without inhibiting
Casp6 may have little effect in preventing the progressive
dementia associated with sporadic or familial AD.
Materials and Methods
Cell culture. Primary human fetal neurons obtained with ethical approval from
the McGill University Institutional Review Board were cultured as described
previously.
36. Brieﬂy, 12-week-old fetal cerebrum were dissociated with trypsin,
Figure 5 APP
WT, APP
Sw or APP
Lo induce Casp6-dependent EGFP-positive neuronal dropout and condensed chromatin. (A) Percentage of EGFP-positive neurons
remaining after 48 and 72h of transfection relative to those measured at 24h of transfection (normalized at 100%, solid line). Transfected neurons were incubated in the
absence ( VEID) or presence (þVEID) of 5mM z-VEID-fmk. Data represents mean±S.E.M. of three independent experiments. *Represents a Po0.01 statistically
signiﬁcant difference between pBudEGFP and pBudEGFP/APP-transfected neurons. ** Represents a statistically signiﬁcant difference between –VEID and þ VEID
(Po0.05). (B) Percentage of EGFP-positive neurons after 48h of pBudEGFP or pBudEGFP /APP
Lo and DN Casp6 co-transfection. Data represents mean±S.E.M. of three
independent experiments. **Represents a Po0.001 statistically signiﬁcant difference between  DN Casp6 andþDN Casp6. (C) Percentage of pBudEGFP, pBudEGFP/
APP
WT, /APP
Sw or /APP
Lo-transfected neurons treated with or without 5mM z-VEID-fmk showing condensed chromatin after 48h post transfection. Data represents the
mean±S.E.M. of three independent experiments (* and ** as in A). (D) Percentage of condensed chromatin-positive neurons co-transfected with pBudEGFP or pBudEGFP/
APP
LoandDNCasp6after48hposttransfection.Datarepresentsmean±S.E.M.ofthreeindependentexperiments.(*and**asinB).(E)EGFP-positivepBudEGFP/APP
Lo-
transfected neuron stained with Hoechst and TUNEL
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Cell Death and Diseasetreated with deoxyribonuclease I, ﬁltered through 130 and 70mm nylon mesh and
plated on poly-lysine coated coverslips or dishes at a density of 3 10
6 cells/ml.
Cultures generally contain B90% neurons and 10% astrocytes. Mouse
neuroblastoma, N2a, cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and maintained in MEM (Gibco-Invitrogen,
Carlsbad, CA, USA) containing 1.5g sodium bicarbonate (Gibco-Invitrogen), 1mM
sodium pyruvate (Gibco-Invitrogen) and 10% fetal bovine serum (HyClone-Thermo
Scientiﬁc, Waltham, MA, USA). Human colon carcinoma (HCT116) cells were
obtained from the American Type Culture Collection and cultured according to
manufacturer’s protocol.
Cloning strategy and site directed mutagenesis of human
APP. Full-length APP695 cDNA (APP
WT) was obtained from Dr. Georges
Levesque (Laval University, Quebec, Canada) and subcloned into the bigenic
eukaryotic pBudEGFP vector-expressing EGFP under the human elongation factor
1 a-promoter. To mimic the state of duplicated APP in familial AD, APPWT cDNA
was subcloned under the human CMV promoter using the HindIII and NotI sites to
generate pBudEGFP/APP
WT. The KM595/596NL Sw mutation and the V642I
LomutationweregeneratedbyQuikChangesitedirectedmutagenesis(Stratagene,
La Jolla, CA, USA) using 50-GATCTCTGAAGTGAATCTGGATGCAGAATTCCG-30
and 50-CATAGCGACAGTGATCATCATCACCTTGGTG-30 primers to generate
pBudEGFP/APP
Sw and pBudEGFP/APP
Lo vectors, respectively. The histidine-
tagged DN Casp6 C163A mutant (DN Casp6) was cloned in the pCep4b vector.
The b-secretase uncleavable APP
MV mutant was a kind gift from Dr. Jannic Boehm
(UniversityofMontreal,Quebec,Canada)
34andwassubclonedintothepBudEGFP
vectorSalIandXbaI restrictionsites. TheLo mutationwas insertedintheAPP
MV by
Quikchange mutagenesis. The pDs-Red RFP-tau (RFP-tau) construct was a kind
gift from Dr. Yasuo Ihara (University of Tokyo, Tokyo, Japan)
42 and the pRFP-C1
monomeric Ub (RFP-Ub) construct was purchased from Addgene (Cambridge,MA,
USA).
43 All constructs were conﬁrmed by sequencing at the McGill University and
Genome Quebec Innovation Centre.
Transfections. Neuronswereplatedon poly-L-lysine(20mg/ml;Sigma-Aldrich,
St Louis, MO, USA) coated polychlorotriﬂuoroethylene Aclar coverslips (Honeywell
Aclar Film; http://www51.honeywell.com/sm/aclar/) at a density of 3 10
6 cells/ml
and were transfected with the Helios gene gun (Bio-Rad, Mississauga, Ontario,
Canada) at a 100p.s.i. pressure pulse of helium. The cartridges used for
transfection were made of 0.033mg of DNA bound to 4.2mg of gold microcarrier
beads prepared in 1M calcium chloride and 0.1ml of 0.05M spermidine.
Approximately 1mg of DNA coated gold beads/cartridge was delivered to three
coverslips of neurons per treatment. When transfecting cells with more than one
construct, a ratio of 2:1 of RFP-tau or RFP-Ub to pBudEGFP, DN Casp6 and
APP
MV or 3:1 of DN Casp6 to APP
Lo was used to prepare cartridges. EGFP-
positive cells were counted versus the total number of cells stained with Hoechst
33342 (Sigma-Aldrich) to estimate the transfection efﬁciency, which was around
0.001%. Primary human neurons resist infection by commonly used viral vectors
and lipid-based methods, and therefore, these methods could not be used for these
studies. HCT116 cells were plated overnight in a six-well plate at a density of
400000 cells per well in McCoy’s media (Gibco-Invitrogen) supplemented with 10%
fetalbovineserum(Fisher,Ottawa,ON, Canada).Transfections wereperformedon
the following day using polyethylenimine (Polysciences Inc., Warrington, PA, USA)
at a 2mg concentration for every 1mg of DNA. The transfection complex was
prepared in 100ml of serum-free media. At 6h following transfection, complete
media was replenished and cells were incubated for an additional 18h to allow for
expression.
Treatment of APP
MV-transfected neurons with Ab peptides.
Fibrillar Abs were prepared as described previously.
44 Cells were transfected as
described above, incubated for 24h and then treated with 50nM Ab1 42 or Ab42 1
control reverse peptide (diluted from a 25mM stock solution in culture media) for
24h before assessing beading and condensed chromatin.
Measurement of neuritic beading in human neurons. Neurons
displayingbeadedEGFPweremeasuredasa percentofthetotalnumberofEGFP-
positive neurons at each 24h time point for up to 72h. Results were obtained by
averaging neuronal counts for at least 50 EGFP-positive neurons per experiment in
three independent neuronal preparations.
Cell death assays: neuronal dropout. The number of EGFP-positive
APP
WT, APP
Sw, APP
Lo, APP
MVor DN Casp6-transfected human neurons in culture
was assessed live over 72h under ﬂuorescence microscopy. For this analysis, the
totalnumberoftransfectedﬂuorescentneuronscountedat24hwasstandardizedto
100% and subsequent neuronal counts at 48 and 72h were expressed as a
percentage of the total number of neurons counted at 24h. A minimum of 50
neurons per experiment in three independent neuronal preparations was assessed.
Condensed chromatin. For condensed chromatin, 1mg/ml of Hoescht
33342 was added to media 20min before the live assessment, cells were washed
twice in PBS pH 7.5 and fresh media was re-applied. EGFP-positive neurons
displaying condensed chromatin visualized with Hoescht 33342 were counted.
Tunel. For DNA fragmentation, human neurons were stained with TUNEL-Red
(Roche, Laval, Quebec, Canada). Brieﬂy, neurons were ﬁxed for 20min at room
temperature in 4% paraformaldehyde and 4% sucrose, and then permeabilized in
0.1% Triton X-100 and 0.1% sodium citrate before the staining.
Immunocytochemistry. Primary human neurons in culture were serum-
deprived from 24–26h and ﬁxed with 4% paraformaldehyde and 4 % sucrose for
20min at room temperature. The ﬁxed cells were permeabilized with 0.1% Triton
X-100 and 0.1% sodium citrate, and treated with 10% goat serum for 20min.
Primary antibodies consisting of anti-Tub (T3526; Sigma-Aldrich, 1/100), anti-tau
(R42from Dr. HemantPaudel,McGill U Montreal,Canada, 1/250)anti-microtubule-
associated protein-2 (monoclonal clone AP20 from Sigma-Aldrich, 1/150) and
anti-neuroﬁlament (culture media from hybridoma JJ29A1AC from Dr. D Bignami’s
Figure6 APPinducesAb-dependentcelldeath.Percentageofcondensedchromatin(%CC)EGFP-positiveneuronstransfectedwith(a)pBudEGFP,pBudEGFP/APP
WT
or pBudEGFP/APP
MV for 48h, (b) pBudEGFP/APP
MV for 24h and treated with 50nM Ab1 42 or 50nM Ab42 1 for another 24h. *Represents a statistically signiﬁcant
difference of Po0.05 from pBudEGFP-transfected neurons. (c) Percentage of condensed chromatin EGFP-positive neurons co-transfected with pBudEGFP/APP
MV and
pCep4b vector (–DN Casp6) or pCep4b-proCasp6C163A (þDN Casp6) and cultured 24h prior to additional 24h treatment with 50nM Ab1 42 or control reverse peptide
Ab42 1. *Represents Po0.05 difference between Ab1 42 and Ab42 1.
#Represents a Po0.05 difference between –DN Casp6 and þDN Casp6
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41CandthenwashedinPBSthreetimesbeforeapplyingCy3Goatanti-mouseIgG
(Millipore, Nepean, Ontario, Canada; 1/500) or Alexa 488 goat anti-rabbit serum
(Molecular Probes, Burlington, Ontario, Canada; 1/500) secondary antibodies.
Detection was done with a Nikon Eclipse TE2000-U ﬂuorescence microscope
(Mississauga, ON, USA). Images were acquired with an Orca-ER CCD camera
(Improvision, Guelph, ON, Canada), Openlab (Improvision) and Adobe Photoshop
6.0 (Ottawa, ON, Canada) softwares.
Casp6 activity. To assess Casp6 activity in APP
WT, APP
Sw, APP
Lo or APP
MV-
transfected neurons, neuronal cultures were pre-treated with 5mM of z-VEID-fmk
(Biomol, Plymouth meeting, PA, USA) for 2h before the gene gun transfections.
Media containing the Casp6 inhibitor was changed every 24h during the live
assessment until the 72h time point. In addition, neurons were co-transfected with
the DN Casp6 as described above. To assess Casp6 activity in HCT116 cells, cells
were harvested in CHAPS buffer (50mM HEPES, 0.1% CHAPS, 0.1mM EDTA,
1mM DTT) containing protease inhibitors and total protein was quantiﬁed by BCA
assay (ThermoScientiﬁc, Rockford, IL, USA). For measurement of Casp6 activity,
ﬂuorogenic Casp activity assays were performed with Stennicke’s buffer (50mM
HEPES, pH 7.4, 100mM NaCl, 0.1% CHAPS, 10mM DTT, 1mM EDTA, 10%
sucrose) containing 10mM Ac-VEID-AFC (Sigma-Aldrich) at 371C using a Bio-Rad
Fluoromarkﬂuorometer(Hercules,CA,USA)atanexcitationwavelengthof390mM
and emission wavelength of 538nM. Measurements were read every 2min for 1h,
and released pmol of AFC was calculated from an AFC standard curve run in
parallel. The reaction was performed in 50ml total volume containing 10mg of total
protein lysate.
WesternblotanalysesofCasp6. Westernblottinganalysiswasperformed
with 30mg of HCT116 total protein lysate prepared in Laemmli buffer and
eletrophoresed on a 15% SDS-PAGE gel. The following antibodies were used for
subsequentdetection.Anti-Casp6polyclonalantiserumfromNeoMarkers(Fremont,
CA, USA) recognized the full length and p20 subunit of Casp6. The anti-p10Casp6
(Pharmingen) monoclonal antibody recognized the p10 subunit and full-length
proCasp6 or proCasp6C163A. The anti-p20Casp6 10630 neoepitope antibody
detecting the cleaved p20 subunit of active Casp6 was made in the laboratory. The
anti-b-actin monoclonal antibody was raised against the 16 amino acids of the
N-terminus of the protein.
Statistical evaluations. Statistical analysis was performed with a one or two
way analysis of variance and Tukey, Scheffe ´ or Bonferroni post hoc test using the
Statview software (SAS Institute Inc., Cary, NC, USA) or Graphpad Prism software
(La Jolla, CA, USA).
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